| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Shandong Buchang Pharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥16.90 |
| 52 Week High | CN¥23.30 |
| 52 Week Low | CN¥14.15 |
| Beta | 0.54 |
| 1 Month Change | -2.26% |
| 3 Month Change | 3.11% |
| 1 Year Change | -16.71% |
| 3 Year Change | -21.06% |
| 5 Year Change | -31.77% |
| Change since IPO | -64.51% |
Recent News & Updates
Shareholder Returns
| 603858 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -1.1% | -2.6% | -2.4% |
| 1Y | -16.7% | -16.1% | -17.0% |
Rentabilidad frente al sector: 603858 igualó al sector CN Pharmaceuticals , que obtuvo un rendimiento del -16.1% el año pasado.
Rentabilidad vs. Mercado: 603858 igualó al mercado CN, que obtuvo un rendimiento del -17% el año pasado.
Price Volatility
| 603858 volatility | |
|---|---|
| 603858 Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CN Market | 11.7% |
| 10% least volatile stocks in CN Market | 5.2% |
Precio estable de las acciones: 603858 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de 603858 (3%) se ha mantenido estable durante el año pasado.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 8,491 | Chao Zhao | https://www.buchang.com |
Shandong Buchang Pharmaceuticals Co., Ltd. se dedica a la investigación y desarrollo, producción y venta de medicamentos en China. La empresa ofrece medicamentos para tratar enfermedades vasculares cardíacas y cerebrales, urinarias y digestivas, respiratorias, ginecológicas y otras, así como la diabetes. Shandong Buchang Pharmaceuticals Co., Ltd.
Shandong Buchang Pharmaceuticals Co., Ltd. Fundamentals Summary
| 603858 fundamental statistics | |
|---|---|
| Market cap | CN¥18.35b |
| Earnings (TTM) | -CN¥2.00b |
| Revenue (TTM) | CN¥13.63b |
1.4x
P/S Ratio-9.4x
P/E RatioIs 603858 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603858 income statement (TTM) | |
|---|---|
| Revenue | CN¥13.63b |
| Cost of Revenue | CN¥4.00b |
| Gross Profit | CN¥9.63b |
| Other Expenses | CN¥11.63b |
| Earnings | -CN¥2.00b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 26, 2024
| Earnings per share (EPS) | -1.81 |
| Gross Margin | 70.64% |
| Net Profit Margin | -14.66% |
| Debt/Equity Ratio | 26.1% |
How did 603858 perform over the long term?
See historical performance and comparison